A. Krishnaraj

Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial

C. Mazer, H. Teoh, A. Quan, 2023, BMC Cardiovascular Disorders.

Vascular regenerative cells in cardiometabolic disease.

E. Bakbak, A. Krishnaraj, Subodh Verma, 2023, Current opinion in cardiology.

Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial

Deepak L. Bhatt, Lawrence A Leiter, M. Lafreniere-Roula, 2022, Circulation.

Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity.

H. Teoh, E. Bakbak, P. Puar, 2023, Cardiovascular research.

GLP-1 receptor agonists and vascular protection.

H. Teoh, A. Quan, J. Butler, 2024, American journal of physiology. Heart and circulatory physiology.

Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial.

C. Mazer, H. Teoh, A. Quan, 2024, Med.

Vascular Regenerative Cell Deficiencies in South Asian Adults.

C. Mazer, H. Teoh, A. Quan, 2024, Journal of the American College of Cardiology.